Albany Molecular, Denovo deal

Albany Molecular granted Denovo exclusive, worldwide rights to liafensine (DB104), a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI). Using its biomarker platform, Denovo hopes to analyze previous liafensine trial data and identify patient populations in which the candidate may treat depression effectively.

Denovo said that the company will likely conduct a Phase IIb or Phase III study in both the U.S. and China, and possibly other undisclosed countries. Both companies declined to disclose financial terms...